Drugs / tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07493460 | Aug 2025 → Oct 2026 expected | immunodeficiency disease | Washington University School of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetanus, diphtheria and acellular pertussis vaccine (Tdap) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493460 ↗ |
| Known as | Tdap | “tetanus, diphtheria and acellular pertussis vaccine (Tdap)” NCT07493460 ↗ |
| Route | Intramuscular | “four licensed vaccines administered intramuscularly at a single visit” NCT07493460 ↗ |